HC Wainwright Brokers Decrease Earnings Estimates for RMTI

Rockwell Medical, Inc. (NASDAQ:RMTI) – Analysts at HC Wainwright lowered their Q1 2027 earnings estimates for Rockwell Medical in a research report issued to clients and investors on Friday, September 11th. HC Wainwright analyst R. Selvaraju now expects that the company will earn $0.02 per share for the quarter, down from their previous forecast of $0.05. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is ($0.76) per share. HC Wainwright also issued estimates for Rockwell Medical’s Q4 2027 earnings at $0.14 EPS and FY2027 earnings at $0.36 EPS.

Several other equities research analysts have also weighed in on RMTI. Wall Street Zen upgraded Rockwell Medical to a “hold” rating in a report on Saturday, July 25th. Weiss Ratings raised shares of Rockwell Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 3rd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Rockwell Medical has an average rating of “Hold” and an average target price of $20.00.

Rockwell Medical Stock Performance

Shares of NASDAQ RMTI opened at $7.78 on Monday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.00 and a current ratio of 3.25. The firm has a market cap of $31.35 million, a price-to-earnings ratio of -5.81 and a beta of 1.64. The business’s 50-day simple moving average is $7.17 and its 200-day simple moving average is $7.83. Rockwell Medical has a 52 week low of $4.89 and a 52 week high of $17.20.

Rockwell Medical (NASDAQ:RMTI) last posted its earnings results on Thursday, August 13th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.10). The company had revenue of $17.78 million for the quarter, compared to the consensus estimate of $17.82 million. Rockwell Medical had a negative net margin of 7.33% and a negative return on equity of 14.03%.

Institutional Trading of Rockwell Medical

An institutional investor recently bought a new stake in Rockwell Medical stock. Corsair Capital Management L.P. bought a new stake in Rockwell Medical, Inc. (NASDAQ:RMTI) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 50,000 shares of the company’s stock, valued at approximately $45,000. Corsair Capital Management L.P. owned approximately 0.13% of Rockwell Medical at the end of the most recent quarter. 23.31% of the stock is currently owned by hedge funds and other institutional investors.

Rockwell Medical Company Profile

Rockwell Medical, Inc is a Delaware?domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.